{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:13:57Z","timestamp":1787026437540,"version":"build-2736575974"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>\n                    Retinoids, natural and synthetic derivatives of vitamin A, have many regulatory functions in human body, including regulating cellular proliferation, differentiation, apoptosis. Moreover, retinoids have been used successfully for the treatment of certain malignancies, especially acute promyelocytic leukemia (APL) in adults and neuroblastoma in children. However, retinoids have not yet been translated into effective systemic treatments for most solid cancers. Some recent studies have shown that retinoids promote tumorigenesis. Therefore, we performed this meta-analysis to systematically evaluate the efficacy of retinoids in the chemoprevention and treatment of cancers. We performed literature search of several electronic databases, including PubMed, Embase and Cochrane Library from 2000 January to 2021 November. Various outcomes were applied to investigate the potential of retinoids for prevention and treatment of cancers. The primary outcomes in this study were disease recurrence and clinical response. The secondary outcomes included overall survival (OS), cancer development, disease progression and event-free survival. We identified 39 randomized controlled trials with 15,627 patients in this study. Our results showed that lower recurrence rate and better clinical response were obtained in retinoids treated patients with cancer or premalignancy as compared with control. The differences were statistically significant (RR = 0.85, 95% CI = 0.74\u20130.96,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.01; RR = 1.24, 95% CI = 1.03\u20131.49,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.02, respectively). Retinoids treatment was not associated with improvement in overall survival, cancer development, disease progression or event-free survival. Subgroup analysis conducted based on cancer type showed that patients benefited from retinoids treatment in APL, renal cell carcinoma, hepatocellular carcinoma, lung cancer, Kaposi sarcoma, and complete hydatidiform mole. No significant therapeutic effect was noted in head and neck cancer, acute myeloid leukemia (AML), melanoma, breast cancer, bladder cancer, cervical intraepithelial neoplasia (CIN) or cervical carcinoma. Subgroup analysis based on tumor classification demonstrated that retinoids group obtained a lower recurrence rate and better clinical response than control group in solid cancers. In conclusion, clinical application of retinoids was associated with reduction in disease recurrence and improvement in clinical response, illustrating that retinoids play a key role in cancer prevention and therapy. Further research is needed to broaden the utility of retinoids in other types of cancers.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Systematic Review Registration:<\/jats:bold>\n                    PROSPERO, identifier CRD42022296706.\n                  <\/jats:p>","DOI":"10.3389\/fgene.2022.1065320","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T01:04:40Z","timestamp":1667955880000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Retinoids in cancer chemoprevention and therapy: Meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Shuting","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinchao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1200\/jco.2005.07.114","article-title":"Randomized phase II\/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: The European organisation for research and treatment of cancer genito-urinary tract cancer group (EORTC 30951)","volume":"23","author":"Aass","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B2","first-page":"567","article-title":"Prevention of post-mole malignant trophoblastic disease with vitamin A","volume":"11","author":"Andrijono","year":"2010","journal-title":"Asian pac. J. Cancer Prev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1200\/JCO.2009.26.6452","article-title":"Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer","volume":"28","author":"Arrieta","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B4","first-page":"0732","volume-title":"Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A prospectively randomized trial of the German cooperative renal carcinoma chemoimmunotherapy group","author":"Atzpodien","year":"2004"},{"key":"B5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1179\/1607845415Y.0000000002","article-title":"Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory\/relapsed cutaneous T-cell lymphoma","volume":"20","author":"Aviles","year":"2015","journal-title":"Hematol. Amst. Neth."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1002\/cncr.11009","article-title":"A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma","volume":"95","author":"Bernstein","year":"2002","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1002\/cncr.30920","article-title":"Double-Blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the eastern cooperative oncology group-ACRIN cancer research group (C0590)","volume":"123","author":"Bhatia","year":"2017","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2165\/00128071-200102020-00004","article-title":"Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma","volume":"2","author":"Bodsworth","year":"2001","journal-title":"Am. J. Clin. Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.2009.22.9088","article-title":"Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial","volume":"28","author":"Burnett","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/ijc.20923","article-title":"Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: Long-term results","volume":"115","author":"Chiesa","year":"2005","journal-title":"Int. J. Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"E132","DOI":"10.3390\/ijms19010132","article-title":"Why differentiation therapy sometimes fails: Molecular mechanisms of resistance to retinoids","volume":"19","author":"Chlapek","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1015-9584(10)60021-8","article-title":"Vitamin analogues in chemoprevention of hepatocellular carcinoma after resection or ablation-a systematic review and meta-analysis","author":"Chu","year":"2010","journal-title":"(Electronic)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/14651858.CD002141","article-title":"Drugs for preventing lung cancer in healthy people","author":"Cort\u00e9s-Jofr\u00e9","year":"2020","journal-title":"(Electronic)"},{"key":"B15","first-page":"2227","volume-title":"Trifarotene: A current review and perspectives in dermatology","author":"Cosio","year":"2021"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/JCO.2008.19.3797","article-title":"Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women","author":"Decensi","year":"2009","journal-title":"(Electronic)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"10981098","DOI":"10.1016\/j.cell.2020.02.042","article-title":"Tumor-derived retinoic acid regulates intratumoral monocyte differentiation to promote immune suppression","volume":"180","author":"Devalaraja","year":"2020","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.leukres.2013.03.001","article-title":"All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American intergroup study I0129","volume":"37","author":"Douer","year":"2013","journal-title":"Leuk. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/sj.leu.2401859","article-title":"Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group","volume":"14","author":"Fenaux","year":"2000","journal-title":"Leukemia"},{"key":"B20","first-page":"3356","article-title":"A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix","volume":"7","author":"Follen","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/cncr.20307","article-title":"Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma","volume":"101","author":"Foss\u00e5","year":"2004","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1371\/journal.pone.0021107","article-title":"Vitamin A and retinoid derivatives for lung cancer: A systematic review and meta analysis","volume":"6","author":"Fritz","year":"2011","journal-title":"(Electronic)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s10552-011-9811-y","article-title":"Retinol, vitamins A, C, and E and breast cancer risk: A meta-analysis and meta-regression","author":"Fulan","year":"2011","journal-title":"(Electronic)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1046\/j.1440-0960.2002.00613.x","article-title":"Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients","volume":"43","author":"George","year":"2002","journal-title":"Australas. J. Dermatol."},{"key":"B25","first-page":"0199","volume-title":"Mechanisms of digestion and absorption of dietary vitamin A","author":"Harrison","year":"2005"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.07.025","article-title":"Vitamin A and breast cancer survival: A systematic review and meta-analysis","volume":"7","author":"He","year":"2018","journal-title":"(Electronic)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/14651858.CD003296.pub3","article-title":"Retinoids for preventing the progression of cervical intra-epithelial neoplasia","volume":"10","author":"Helm","year":"2013","journal-title":"(Electronic)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1002\/ski2.107","article-title":"Topical treatments for Kaposi sarcoma: A systematic review","volume":"2","author":"Htet","year":"2022","journal-title":"Skin. Health Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1002\/cncr.26374","article-title":"Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251)","volume":"118","author":"Kadakia","year":"2012","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1080\/09546634.2017.1309349","article-title":"Retinoids: A journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects","volume":"28","author":"Khalil","year":"2017","journal-title":"(Electronic)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jnci\/djj091","article-title":"Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients","volume":"98","author":"Khuri","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"B32","doi-asserted-by":"publisher","first-page":"0008","DOI":"10.1158\/0008-5472.CAN-04-4562","article-title":"The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer","author":"Kim","year":"2005","journal-title":"(Print)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1054\/bjoc.2000.1425","article-title":"A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy","volume":"83","author":"Kohler","year":"2000","journal-title":"Br. J. Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1146\/annurev-immunol-041015-055427","article-title":"Retinoic acid and retinoic acid receptors as pleiotropic modulators of the immune system","volume":"36","author":"Larange","year":"2016","journal-title":"(Electronic)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1158\/1940-6207.Capr-09-0124","article-title":"Mortality in the randomized, controlled lung intergroup trial of isotretinoin","volume":"3","author":"Lee","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jnci\/93.8.605","article-title":"Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer","volume":"93","author":"Lippman","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1200\/JCO.2000.18.16.2972","article-title":"Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma","volume":"18","author":"Motzer","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fonc.2013.00218","article-title":"The addition of all-trans retinoic acid to chemotherapy may not improve the outcome of patient with NPM1 mutated acute myeloid leukemia","volume":"3","author":"Nazha","year":"2013","journal-title":"Front. Oncol."},{"key":"B39","first-page":"1549","article-title":"The success and the challenge of all-trans retinoic acid in the treatment of cancer","volume":"59","author":"Ni","year":"2019","journal-title":"(Electronic)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00535-014-0996-1","article-title":"Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial","volume":"50","author":"Okita","year":"","journal-title":"J. Gastroenterol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00535-014-0956-9","article-title":"Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: A randomized double-blind placebo-controlled study","volume":"50","author":"Okita","year":"","journal-title":"(Electronic)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/archotol.131.3.198","article-title":"Chemoprevention of head and neck cancer with retinoids: A negative result","volume":"131","author":"Perry","year":"2005","journal-title":"Arch. Otolaryngol. Head. Neck Surg."},{"key":"B43","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1007\/s12032-010-9682-1","article-title":"Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): An intergroup trial coordinated by the Eastern Cooperative Oncology Group","volume":"28","author":"Rao","year":"2011","journal-title":"Med. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"8655","DOI":"10.1200\/JCO.2004.00.8128","article-title":"Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European cooperative adjuvant melanoma treatment study group","volume":"23","author":"Richtig","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/s0029-7844(02)01949-x","article-title":"Isotretinoin for low-grade cervical dysplasia in human immunodeficiency virus-infected women","volume":"99","author":"Robinson","year":"2002","journal-title":"Obstet. Gynecol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1055-9965.2148.13.12","article-title":"Low-dose topical delivery of all-trans retinoic acid for cervical intraepithelial neoplasia II and III","volume":"13","author":"Ruffin","year":"2004","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"B47","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1158\/1078-0432.CCR-07-0733","article-title":"Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer","volume":"14","author":"Sabichi","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.31557\/apjcp.2019.20.7.2213","article-title":"Outcome of combined neoadjuvant chemotherapy and vitamin A in advanced cervical carcinoma: A randomized double-blind clinical trial","volume":"20","author":"Sanusi","year":"2019","journal-title":"Asian pac. J. Cancer Prev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1358\/mf.2006.28.2.977843","article-title":"Evaluation of the clinical and histological effectiveness of isotretinoin in the therapy of oral leukoplakia: Ten years of experience: Is management still up to date and effective?","volume":"28","author":"Scardina","year":"2006","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.1073\/pnas.0400053101","article-title":"All-trans retinoic acid\/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia","volume":"101","author":"Shen","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1200\/JCO.2013.53.3570","article-title":"Tamibarotene as maintenance therapy for acute promyelocytic leukemia: Results from a randomized controlled trial","volume":"32","author":"Shinagawa","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000082093","article-title":"Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma: Updated analysis of the long-term follow-up data","volume":"48","author":"Takai","year":"2005","journal-title":"Intervirology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1186\/1477-7819-12-130","article-title":"Vitamin A and risk of bladder cancer: A meta-analysis of epidemiological studies","author":"Tang","year":"2014","journal-title":"(Electronic)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1146\/annurev-pathol-011110-130303","article-title":"Retinoids, retinoic acid receptors, and cancer","volume":"6","author":"Tang","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3892\/or.11.6.1297","article-title":"13-cis retinoic acid in head and neck cancer chemoprevention: Results of a randomized trial from the Italian head and neck chemoprevention study group","volume":"11","author":"Toma","year":"2004","journal-title":"Oncol. Rep."},{"key":"B56","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/jnci\/92.12.977","article-title":"EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European organization for research and treatment of cancer head and neck and lung cancer cooperative groups","volume":"92","author":"van Zandwijk","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/annonc\/mdl047","article-title":"Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer","volume":"17","author":"Veronesi","year":"2006","journal-title":"Ann. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/jid.2011.483","article-title":"Tretinoin and the prevention of keratinocyte carcinoma (basal and squamous cell carcinoma of the skin): A veterans affairs randomized chemoprevention trial","volume":"132","author":"Weinstock","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1001\/archdermatol.2008.542","article-title":"Topical tretinoin therapy and all-cause mortality","volume":"145","author":"Weinstock","year":"2009","journal-title":"Arch. Dermatol."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/nu7115463","article-title":"Association of dietary vitamin A and \u03b2-carotene intake with the risk of lung cancer: A meta-analysis of 19 publications","volume":"7","author":"Yu","year":"2015","journal-title":"(Electronic)"},{"key":"B61","first-page":"1095","article-title":"Vitamin A and risk of cervical cancer: A meta-analysis","volume":"124","author":"Zhang","year":"2012","journal-title":"Electronic"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.1065320\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T01:04:47Z","timestamp":1667955887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.1065320\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":61,"alternative-id":["10.3389\/fgene.2022.1065320"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2022.1065320","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"article-number":"1065320"}}